Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Furst

Showing results (31-40 of 1,662) with videos related to

Pageof 167
Sort By:
The Journal of Rheumatology. Supplement|April 1, 1992
Toxicity of antirheumatic medications in children with juvenile arthritisD E Furst
Annals of the New York Academy of Sciences|November 30, 1993
Optimizing combination chemotherapy for rheumatoid arthritisD E Furst
Pharmacotherapy|September 1, 1983
Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritisD E Furst
The Journal of Rheumatology. Supplement|October 1, 1988
Clinically important interactions of nonsteroidal antiinflammatory drugs with other medicationsD E Furst
The Psychoanalytic Study of the Child|February 17, 1999
A psychoanalytic study of aggressionS S Furst
Agents and Actions. Supplements|January 1, 1985
Significance of NSAID serum to response relationshipsD E Furst
Environmental Science & Technology|February 25, 2025
Quantitative Evaluation of Regulatory Indicators for Brominated Haloacetic Acids in Drinking WaterKirin Emlet Furst
The Journal of Rheumatology. Supplement|December 1, 1985
Clinical pharmacology of very low dose methotrexate for use in rheumatoid arthritisD E Furst
Clinical and Experimental Rheumatology|June 26, 2010
Development of TNF inhibitor therapies for the treatment of rheumatoid arthritisDaniel E Furst
Seminars in Arthritis and Rheumatism|October 1, 1990
Proposition: methotrexate should not be the first second-line agent to be used in rheumatoid arthritis if NSAIDs failD E Furst
Pageof 167

Showing results (31-40 of 1,662) with videos related to

Sort By:
Pageof 167
The Journal of Rheumatology. Supplement|April 1, 1992
Toxicity of antirheumatic medications in children with juvenile arthritisD E Furst
Annals of the New York Academy of Sciences|November 30, 1993
Optimizing combination chemotherapy for rheumatoid arthritisD E Furst
Pharmacotherapy|September 1, 1983
Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritisD E Furst
The Journal of Rheumatology. Supplement|October 1, 1988
Clinically important interactions of nonsteroidal antiinflammatory drugs with other medicationsD E Furst
The Psychoanalytic Study of the Child|February 17, 1999
A psychoanalytic study of aggressionS S Furst
Agents and Actions. Supplements|January 1, 1985
Significance of NSAID serum to response relationshipsD E Furst
Environmental Science & Technology|February 25, 2025
Quantitative Evaluation of Regulatory Indicators for Brominated Haloacetic Acids in Drinking WaterKirin Emlet Furst
The Journal of Rheumatology. Supplement|December 1, 1985
Clinical pharmacology of very low dose methotrexate for use in rheumatoid arthritisD E Furst
Clinical and Experimental Rheumatology|June 26, 2010
Development of TNF inhibitor therapies for the treatment of rheumatoid arthritisDaniel E Furst
Seminars in Arthritis and Rheumatism|October 1, 1990
Proposition: methotrexate should not be the first second-line agent to be used in rheumatoid arthritis if NSAIDs failD E Furst
Pageof 167